vTv Therapeutics Inc logo

vTv Therapeutics Inc - Class A

FRA:5VT0 (USA)   Class A
€ 26.40 (+0.76%) May 23
At Loss
P/B:
3.39
Market Cap:
€ 64.95M ($ 70.41M)
Enterprise V:
€ 16.95M ($ 18.38M)
Volume:
-
Avg Vol (2M):
-
Also Trade In:
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for vTv Therapeutics Inc ( FRA:5VT0 ) from 2015 to May 24 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. vTv Therapeutics stock (FRA:5VT0) PE ratio as of May 24 2024 is 0. More Details

vTv Therapeutics Inc (FRA:5VT0) PE Ratio (TTM) Chart

To

vTv Therapeutics Inc (FRA:5VT0) PE Ratio (TTM) Historical Data

Total 1280
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 15
vTv Therapeutics PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-05-24 At Loss 2024-03-22 At Loss
2024-05-23 At Loss 2024-03-21 At Loss
2024-05-22 At Loss 2024-03-20 At Loss
2024-05-21 At Loss 2024-03-19 At Loss
2024-05-20 At Loss 2024-03-18 At Loss
2024-05-17 At Loss 2024-03-15 At Loss
2024-05-16 At Loss 2024-03-14 At Loss
2024-05-15 At Loss 2024-03-13 At Loss
2024-05-14 At Loss 2024-03-12 At Loss
2024-05-13 At Loss 2024-03-11 At Loss
2024-05-10 At Loss 2024-03-08 At Loss
2024-05-09 At Loss 2024-03-07 At Loss
2024-05-08 At Loss 2024-03-06 At Loss
2024-05-07 At Loss 2024-03-05 At Loss
2024-05-06 At Loss 2024-03-04 At Loss
2024-05-03 At Loss 2024-03-01 At Loss
2024-05-02 At Loss 2024-02-29 At Loss
2024-05-01 At Loss 2024-02-28 At Loss
2024-04-30 At Loss 2024-02-27 At Loss
2024-04-29 At Loss 2024-02-26 At Loss
2024-04-26 At Loss 2024-02-23 At Loss
2024-04-25 At Loss 2024-02-22 At Loss
2024-04-24 At Loss 2024-02-21 At Loss
2024-04-23 At Loss 2024-02-20 At Loss
2024-04-22 At Loss 2024-02-19 At Loss
2024-04-19 At Loss 2024-02-16 At Loss
2024-04-18 At Loss 2024-02-15 At Loss
2024-04-17 At Loss 2024-02-14 At Loss
2024-04-16 At Loss 2024-02-13 At Loss
2024-04-15 At Loss 2024-02-12 At Loss
2024-04-12 At Loss 2024-02-09 At Loss
2024-04-11 At Loss 2024-02-08 At Loss
2024-04-10 At Loss 2024-02-07 At Loss
2024-04-09 At Loss 2024-02-06 At Loss
2024-04-08 At Loss 2024-02-05 At Loss
2024-04-05 At Loss 2024-02-02 At Loss
2024-04-04 At Loss 2024-02-01 At Loss
2024-04-03 At Loss 2024-01-31 At Loss
2024-04-02 At Loss 2024-01-30 At Loss
2024-04-01 At Loss 2024-01-29 At Loss
2024-03-29 At Loss 2024-01-26 At Loss
2024-03-28 At Loss 2024-01-25 At Loss
2024-03-27 At Loss 2024-01-24 At Loss
2024-03-26 At Loss 2024-01-23 At Loss
2024-03-25 At Loss 2024-01-22 At Loss

vTv Therapeutics Inc (FRA:5VT0) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

vTv Therapeutics Inc logo
vTv Therapeutics Inc
NAICS : 325412 SIC : 2834
ISIN : US9183851057

Share Class Description:

FRA:5VT0: Class A
Description
vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. Itsproduct pipeline include TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.